Topas Therapeutics GMBH
https://topas-therapeutics.com/topas/home/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Topas Therapeutics GMBH
First Wave To Merge With ImmunogenX With Focus On Celiac Disease
Troubled by recent clinical disappointments, First Wave will combine with ImmunogenX to focus on that company’s Phase III-ready enzyme replacement therapy for celiac disease. A deep-pocketed partner waits in the wings.
Topas To Enter Clinic In 2018
Timm Jessen, CEO of Topas Therapeutics, talks to Scrip's Lucie Ellis about his journey through the pharma and biotech sector and what lies ahead for his current company.
Deals Shaping The Medical Industry, September 2017
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2017.
Topas Bags Big Pharma Partner With Lilly Pact
Eli Lilly is impressed with the privately held German biotech spun out of Evotec which is pursuing a novel liver-based immune tolerance approach.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Nanotechnology, Chips, etc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice